Tissue Regenix Group plc
Company Profile
Company website
Sector
Pharmaceuticals & Biotechnology (Biotechnology)
Description
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
Not all Walbrook clients have a handy 2 page summary available. Click on "Register your interest" and we'll let the Company know that you think this would be useful
Latest Company Summary
Investor Access
Event information
Venue
Time
Financial Calendar
| Event | Date |
| Year End | 31 December |
| Half Year End | 30 June |
| Preliminary Results* | June |
| Interim Results* | September |
| AGM* | June |
* Months based on previous announcements of this kind
